Universal flu vaccine takes first step in human trial
NCT ID NCT05901636
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new universal flu vaccine (INFLUENZA G1 mHA) in 170 healthy adults aged 18-45. The goal was to check if it is safe and triggers an immune response. Participants received either the vaccine with or without an adjuvant, or a placebo. Results will show if this approach could lead to a vaccine that works against many flu types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INFLUENZA G1 mini-hemagglutinin stem-derived protein (mHA) with or without aluminum hydroxide adjuvant
- What this could lead to
- If successful, this could lead to a universal flu vaccine that protects against many flu strains, reducing the need for yearly shots.
- What could go wrong
- This is an early-phase trial (Phase 1/2a) focused on safety, not yet proven to prevent flu. The vaccine may not trigger strong enough immunity or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTI Clinical Trial and Consulting Services
Cincinnati, Ohio, 45212, United States
-
Clinical Trials Managements, LLC
Metairie, Louisiana, 70006, United States
-
Floridian Clinical Research LLC
Miami Lakes, Florida, 33016, United States
-
Johnson County Clin-Trials
Lenexa, Kansas, 66219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.